Nicole G Chau1, Shelley Hurwitz2, Chelsey M Mitchell3, Alexandra Aserlind3, Noam Grunfeld3, Leah Kaplan3, Peter Hsi3, Daniel E Bauer1,4,5, Christopher S Lathan1, Carlos Rodriguez-Galindo4,5, Roy B Tishler6, Robert I Haddad1, Stephen E Sallan4,5, James E Bradner1, Christopher A French3. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2. Center for Clinical Investigation, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 5. Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: NUT midline carcinoma is a rare and aggressive genetically characterized subtype of squamous cell carcinoma frequently arising from the head and neck. The characteristics and optimal management of head and neck NUT midline carcinoma (HNNMC) are unclear. METHODS: A retrospective review of all known cases of HNNMC in the International NUT Midline Carcinoma Registry as of December 31, 2014, was performed. Forty-eight consecutive patients were treated from 1993 to 2014, and clinicopathologic variables and outcomes for 40 patients were available for analyses; they composed the largest HNNMC cohort studied to date. Overall survival (OS) and progression-free survival (PFS) according to patient characteristics and treatment were analyzed. RESULTS: This study identified a 5-fold increase in the diagnosis of HNNMC from 2011 to 2014. The median age was 21.9 years (range, 0.1-81.7 years); the male and female proportions were 40% and 60%, respectively; and 86% had bromodomain containing 4-nuclear protein in testis (BRD4-NUT) fusion. The initial treatment was initial surgery with or without adjuvant chemoradiation or adjuvant radiation (56%), initial radiation with or without chemotherapy (15%), or initial chemotherapy with or without surgery or radiation (28%). The median PFS was 6.6 months (range, 4.7-8.4 months). The median OS was 9.7 months (range, 6.6-15.6 months). The 2-year PFS rate was 26% (95% confidence interval [CI], 13%-40%). The 2-year OS rate was 30% (95% CI, 16%-46%). Initial surgery with or without postoperative chemoradiation or radiation (P = .04) and complete resection with negative margins (P = .01) were significant predictors of improved OS even after adjustments for age, tumor size, and neck lymphadenopathy. Initial radiation or chemotherapy and the NUT translocation type were not associated with outcomes. CONCLUSIONS: HNNMC portends a poor prognosis. Aggressive initial surgical resection with or without postoperative chemoradiation or radiation is associated with significantly enhanced survival. Chemotherapy or radiation alone is often inadequate. Cancer 2016;122:3632-40.
BACKGROUND:NUT midline carcinoma is a rare and aggressive genetically characterized subtype of squamous cell carcinoma frequently arising from the head and neck. The characteristics and optimal management of head and neck NUT midline carcinoma (HNNMC) are unclear. METHODS: A retrospective review of all known cases of HNNMC in the International NUT Midline Carcinoma Registry as of December 31, 2014, was performed. Forty-eight consecutive patients were treated from 1993 to 2014, and clinicopathologic variables and outcomes for 40 patients were available for analyses; they composed the largest HNNMC cohort studied to date. Overall survival (OS) and progression-free survival (PFS) according to patient characteristics and treatment were analyzed. RESULTS: This study identified a 5-fold increase in the diagnosis of HNNMC from 2011 to 2014. The median age was 21.9 years (range, 0.1-81.7 years); the male and female proportions were 40% and 60%, respectively; and 86% had bromodomain containing 4-nuclear protein in testis (BRD4-NUT) fusion. The initial treatment was initial surgery with or without adjuvant chemoradiation or adjuvant radiation (56%), initial radiation with or without chemotherapy (15%), or initial chemotherapy with or without surgery or radiation (28%). The median PFS was 6.6 months (range, 4.7-8.4 months). The median OS was 9.7 months (range, 6.6-15.6 months). The 2-year PFS rate was 26% (95% confidence interval [CI], 13%-40%). The 2-year OS rate was 30% (95% CI, 16%-46%). Initial surgery with or without postoperative chemoradiation or radiation (P = .04) and complete resection with negative margins (P = .01) were significant predictors of improved OS even after adjustments for age, tumor size, and neck lymphadenopathy. Initial radiation or chemotherapy and the NUT translocation type were not associated with outcomes. CONCLUSIONS: HNNMC portends a poor prognosis. Aggressive initial surgical resection with or without postoperative chemoradiation or radiation is associated with significantly enhanced survival. Chemotherapy or radiation alone is often inadequate. Cancer 2016;122:3632-40.
Keywords:
NUT midline carcinoma; bromodomain containing 3-nuclear protein in testis (BRD3-NUT); bromodomain containing 4-nuclear protein in testis (BRD4-NUT); head and neck cancer; nuclear protein in testis (NUT) protein
Authors: Christopher A French; Jeffery L Kutok; William C Faquin; Jeffrey A Toretsky; Cristina R Antonescu; Constance A Griffin; Vania Nose; Sara O Vargas; Mary Moschovi; Fotini Tzortzatou-Stathopoulou; Isao Miyoshi; Antonio R Perez-Atayde; Jon C Aster; Jonathan A Fletcher Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French Journal: Oncogene Date: 2013-04-22 Impact factor: 9.867
Authors: Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Christopher A French; Shaila Rahman; Erica M Walsh; Simone Kühnle; Adlai R Grayson; Madeleine E Lemieux; Noam Grunfeld; Brian P Rubin; Cristina R Antonescu; Songlin Zhang; Rajkumar Venkatramani; Paola Dal Cin; Peter M Howley Journal: Cancer Discov Date: 2014-05-29 Impact factor: 39.397
Authors: Herbert Haack; Laura A Johnson; Christopher J Fry; Katherine Crosby; Roberto D Polakiewicz; Edward B Stelow; Seung-Mo Hong; Brian E Schwartz; Michael J Cameron; Mark A Rubin; Martin C Chang; Jon C Aster; Christopher A French Journal: Am J Surg Pathol Date: 2009-07 Impact factor: 6.394
Authors: C A French; C L Ramirez; J Kolmakova; T T Hickman; M J Cameron; M E Thyne; J L Kutok; J A Toretsky; A K Tadavarthy; U R Kees; J A Fletcher; J C Aster Journal: Oncogene Date: 2007-10-15 Impact factor: 9.867
Authors: Artyom A Alekseyenko; Erica M Walsh; Xin Wang; Adlai R Grayson; Peter T Hsi; Peter V Kharchenko; Mitzi I Kuroda; Christopher A French Journal: Genes Dev Date: 2015-07-15 Impact factor: 11.361
Authors: Inga-Marie Schaefer; Paola Dal Cin; Latrice M Landry; Christopher D M Fletcher; Glenn J Hanna; Christopher A French Journal: Genes Chromosomes Cancer Date: 2018-08-14 Impact factor: 5.006
Authors: Huiying Wang; Vivian L Weiss; Robert D Hoffman; Ty Abel; Richard H Ho; Scott C Borinstein; Kyle Mannion; Julia A Bridge; Jennifer Black; Jiancong Liang Journal: Head Neck Pathol Date: 2020-02-19
Authors: Henrik Hellquist; Christopher A French; Justin A Bishop; Andrés Coca-Pelaz; Evan J Propst; António Paiva Correia; Bo-Yee Ngan; Ronald Grant; Nicole A Cipriani; David Vokes; Rui Henrique; Fernando Pardal; Jose Ramon Vizcaino; Alessandra Rinaldo; Alfio Ferlito Journal: Histopathology Date: 2017-02-21 Impact factor: 5.087
Authors: Nolan B Seim; Ramez H W Philips; Lynn Schoenfield; Theodoros N Teknos; James W Rocco; Amit Agrawal; Enver Ozer; Ricardo L Carrau; Stephen Y Kang; Matthew O Old Journal: Head Neck Pathol Date: 2017-03-27
Authors: Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta Journal: Head Neck Pathol Date: 2018-11-22
Authors: Matthew R Avenarius; Cecelia R Miller; Michael A Arnold; Selene Koo; Ryan Roberts; Martin Hobby; Thomas Grossman; Yvonne Moyer; Richard K Wilson; Elaine R Mardis; Julie M Gastier-Foster; Ruthann B Pfau Journal: J Mol Diagn Date: 2020-08-01 Impact factor: 5.568